Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495777 | 0.82 | LMNA (0.41) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL10008076 | 0.81 | HSD17B10 (0.43) | KDM4EALDH1A1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL24392298 | 0.78 | CYP1A2 (0.49) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL5863570 | 0.78 | CYP1A2 (0.49) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL28896612 | 0.75 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL28896517 | 0.75 | TSHR (0.46) | KDM4EALDH1A1SMN1; SMN2LMNAUSP2 | |
| SCHEMBL8832185 | 0.74 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL17027606 | 0.73 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL1492325 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9895658 | 0.72 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345243-A1 | 1H-PYROLLO[3,2-D]PYRIMIDINEDIONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2566868-A1 | PYRROLO [3, 2 -D]PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012119979-A1 | 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-2475660-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011138307-A1 | PYRROLO [3, 2 -D] PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | PRKAB1, PRKAG1, PRKAB2 | KDM4E 1540/4885ALDH1A1 1202/4885HPGD 499/4885 |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | PRKAG2, PRKAB2, PRKAG3 | KDM4E 2191/4885ALDH1A1 1451/4885HPGD 777/4885 |
| US-20130345243-A1 | 1H-PYROLLO[3,2-D]PYRIMIDINEDIONE DERIVATIVES | PRKAB1, PRKAG1, PRKAB2 | KDM4E 1747/4885ALDH1A1 913/4885HPGD 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.